Research reveals how ectopic NMDA receptor expression in triple-negative breast cancer triggers autoimmune disease through antibody maturation. The study shows NMDAR expression recruits B cells and drives affinity maturation, producing antibodies that can cross the blood-brain barrier and cause neurological symptoms while constraining tumor growth.
New research demonstrates that physical activity after cancer diagnosis reduces mortality risk in less common cancers and enhances circadian clock function in tumor tissue, supporting exercise as a therapeutic intervention.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06834672 |
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
RECRUITING | PHASE3 |
| NCT06787807 |
Proteomic Analysis of Patients Undergoing Bariatric Surgery |
NOT_YET_RECRUITING | NA |
| NCT02734004 |
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT02331251 |
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) |
TERMINATED | PHASE1/PHASE2 |
| NCT01078662 |
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats |
COMPLETED | PHASE2 |
| NCT00972205 |
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors |
COMPLETED | NA |
| NCT00888810 |
Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer |
TERMINATED | PHASE2 |
| NCT00423254 |
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. |
COMPLETED | PHASE1 |
